tbuckley/cabot-search huggingface dataset:
Characteristics of Four New Human Cell Lines Derived From Squamous Cell Carcinomas of the Head and Neck&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: H T Rupniak, C Rowlatt, E B Lane, J G Steele, L K Trejdosiewicz, B Laskiewicz, S Povey, B T Hill
Journal: JNCI Journal of the National Cancer Institute (1985)

Four human cell lines were established from biopsy specimens of squamous cell carcinomas of the larynx (TR131 and TR138), tongue (TR126), and buccal mucosa that had infiltrated a lymph node (TR146). All 4 lines readily formed colonies on a plastic substratum, but they were virtually incapable of forming colonies in an anchorage-independent semisolid support system of soft agar (cloning efficiencies, less than 0.02%). The proliferation of this group of tumor-derived cell lines, therefore, appeared to be highly anchorage dependent. Keratin filaments could be visualized in each line by indirect immunofluorescence with the use of polyclonal or monoclonal antibodies to keratins; staining with monospecific antibodies indicated that 3 of the 4 lines expressed simple epithelial keratins 8 and 18, whereas 1 of the 4 also expressed keratin 19. A panel of lectins revealed characteristic localization patterns distinct from those observed on other epithelial cell lines. Cells from 3 lines (TR131, TR138, and TR146) inoculated into nude mice (nu/nu) produced cystic nodules or unequivocal tumors having a histology indicating a squamous cell origin for the injected cells. Electron microscopy demonstrated that the cell lines covered a spectrum of differentiation capability ranging from the undifferentiated monolayer cultures of TR126 to the rather well differentiated, stratified cultures of TR131.
Abstract 12709: Decreased Strength of Quadriceps Increases the Risk of Mortality in Patients with Chronic Heart Failure.
Authors: Kentaro Kamiya, Takashi Masuda, Atsuhiko Matsunaga, Kazumasa Miida, Misao N Ogura, Masahiko Kimura, Chiharu Noda, Minako Ymaoka-Tojo, Takayuki Inomata, Tohru Izumi
Journal: Circulation (2010)

Background: Although cardiac cachexia is characterized by an exaggerated loss of skeletal muscle mass and muscle weakness, the diagnostic value of its muscle weakness was still undetermined. The pu...
Correction of Modal DNA Values Obtained by Microspectrophotometry and Tests for Their Shifts
Authors: Takashi Okagaki, Masuru Izuo
Journal: JNCI Journal of the National Cancer Institute (1978)

The technical problems in the application of statistical analyses of the nuclear DNA contents measured by plug or two-wavelength Feulgen microspectrophotometry were discussed. The skewness of the nuclear DNA content unimodally distributed in a cluster could be corrected by logarithmic transformation. A mean value of the logarithmically transformed DNA contents was a more logical characterization of cancer than a graphically obtained mode of nontransformed values. Equations were derived to estimate the number of cells in the G1- and S-phases of mitotic cycles contained within the cluster and to estimate the correction factor of the mean of transformed values of cells in the G1-phase. Thus statistical tests for a shift in the nuclear DNA content of the cells in question in the G1-phase from that of control cells were made possible.
Selecting treatment for children with acute lymphoblastic leukemia.
Authors: D Pinkel
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.1.4 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8558218 Selecting treatment for children with acute lymphoblastic leukemia. D PinkelxD PinkelSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.1.4 First Page PDF © 1996 by American Society of Clinical Oncology
Reduction of N-Nitroso-N-ethylurea-Induced Neurogenic Tumors by X-Radiation: A Life-Span Study in Rats23
Authors: John F. Knowles
Journal: JNCI Journal of the National Cancer Institute (1984)

Whole-body X-irradiation after neonatal injection with N-nitroso-N-ethylurea (ENU) significantly reduced the incidence of induced neurogenic tumors in inbred HMT rats kept for their complete life-span. After administration of 10 mg ENU/kg and 1.25 Gy X-radiation, the incidence of schwannomas but not of gliomas was reduced as compared to the incidence in rats given 10 mg ENU/kg only. In contrast, after administration of 4 mg ENU/kg, 1.25 Gy reduced the incidence of gliomas but not of schwannomas. Administration of 1.25 Gy alone induced a remarkably high incidence of rats with neurogenic tumors (20%). Latency of tumor detection was not significantly affected by radiation. Among the most frequently occurring nonneurogenic tumors, squamous cell carcinomas were reduced in incidence by treatment with ENU, 1.25 Gy X-radiation, or both combined. No treatment affected the incidence of pituitary or mammary tumors. There was a preponderance of ovarian tumors in rats given 4 mg ENU/kg + 1.25 Gy. An incidental finding was the occurrence of granular cell tumors in 7 rats from different treatment groups.
Phase II trial of oxaliplatin and gemcitabine with bevacizumab in first-line advanced non-small cell lung cancer (NSCLC)
Authors: E. Davila, R. Lilenbaum, L. Raez, L. Seigel, J. Tseng, P. Graham
Journal: Journal of Clinical Oncology (2006)

17009 Background: Oxaliplatin-Gemcitabine (GemOx) is an active and well tolerated. Bevacizumab (BV) prolongs survival when combined with carboplatin-paclitaxel. This phase II trial evaluates the efficacy of GemOx + BV as 1 st line therapy for advanced NSCLC patients. Methods: Pts with stage IIIB (effusion) and IV non-squamous NSCLC, ECOG PS 0 or 1, no CNS metastasis, and no other contraindications to BV, are eligible. Prior therapy for earlier-stage disease allowed if completed at least 12 months before enrollment. Treatment consists of Gem 1000 mg/m 2 on d1 and 8, Ox 130 mg/m 2 on d1, and BV 15 mg/kg on d1, repeated every 3 wks for a total 4 cycles. Pts who respond or have stable disease receive BV maintenance until progression. Main endpoints are response rate (RR), grade (Gr) 3–4 toxicities, time to progression (TTP), and overall survival (OS). Results: As of 12/05, 26 out of 50 projected pts have been enrolled from 4 institutions. M/F 17/9; median age 65y (45,81); IIIB/IV 3/23; PS 0/1 8/18. Median F/U time is 3.7 months. 24 pts are evaluable for toxicity: 1Gr3 ANC; 1Gr3 and 4 PLT; no FN.3 Gr3 diarrhea and 2 Gr3 N/V; 1Gr3 and 4 hypophosphatemia; 1 pt had ischemic bowel after the 1 st cycle, recovered fully and was removed from study; 1 pt died of liver failure in the 1 st cycle. No bleeding complications have occurred. 22 pts are evaluable for RR (ITT): 7 PR (31%); 8 SD (36%). TTP and OS data not yet available. Conclusions: This is the first report of GemOx in combination with BV in advanced NSCLC. This regimen has minimal hematologic toxicity but selected non-hematologic toxicities are noted. Activity appears promising and merits further investigation. Accrual is ongoing. [Table: see text]
The occurrence of idiopathic secondary post-transplant thrombocytopenia and the kinetics of platelet recovery predict survival in patients undergoing autologous hematopoietic progenitor cell transplantation
Authors: E. Waller, M. J. Ninan, J. Roback, M. Arellano, C. Flowers
Journal: Journal of Clinical Oncology (2007)

7109 Background: The frequency and clinical significance of secondary thrombocytopenia following initial engraftment in autologous hematopoietic progenitor cell transplantation (HPCT) is unknown. Methods: An IRB-approved retrospective study of thrombopoiesis in 359 patients transplanted with autologous blood (97%) or marrow (3%) who achieved transfusion-independent platelet engraftment to &gt;50,000/mcL. Idiopathic secondary post-transplant thrombocytopenia (ISPT) was defined as &gt;50% decline in blood platelets to &lt;100,000/mcL in the absence of relapse or sepsis. Results: 62 of 359 study subjects (17%) met the criteria for ISPT within the first 100 days post-transplant. Patients with ISPT had more rapid platelet engraftment (17 + 5 days) versus non-ISPT patients (18 + 18 days; p=0.002) and partial recovery of platelet counts (median 96K/mcL) by day 75 post-transplant. The median survival for the entire population was 6.2 years with shorter survival in AML (1.3 years), breast cancer (6.2 years) and myeloma (5.5 years) than lymphoma patients (median not reached). Co- variates associated with post-transplant death (p&lt;0.1) were entered into a multivariable logistic regression analysis stratified by cancer diagnosis at the time of transplant. Three factors were independently associated with worse survival: the number of prior chemotherapy regimens, failure to achieve a normal platelet counts post-transplant, and the occurrence of ISPT. A prognostic score was developed based upon the occurrence of ISPT and post-transplant platelet counts of &lt;150,000/mcL. Survival of patients with both factors (n=25) was poor (15% alive at 5 years); patients with one factor (n=145) had 49% 5-year survival; patients with 0 factors (n=189) had 72% 5-year survival. Patients who failed to achieve a normal post-transplant platelet count received significantly fewer CD34+ cells/kg (P&lt;0.001), while patients with ISPT received fewer CD34+CD38- cells/kg (P=0.001). Conclusion: ISPT reflects poor engraftment with long-term-repopulating CD34+ CD38- stem cells. The quantity and quality of autologous HPC in the graft are important prognostic variables for long-term survival. No significant financial relationships to disclose.
The Countdown to 2020: measuring progress in neglected tropical diseases
Authors: Kebede Deribe
Journal: The Lancet Global Health (2016)

The London Declaration on Neglected Tropical Diseases1 marked its fourth year on Jan 30, 2016. The declaration represents a coordinate effort to control or eliminate ten of the neglected diseases by 2020, and has already led to important coordination and partnership, and mobilised considerable resources. Although the progress made so far is to be celebrated, now is the time to count down to 2020 and start monitoring the progress and trends towards achieving the control and elimination targets.
Qualitative review of hazing in collegiate and school sports: consequences from a lack of culture, knowledge and responsiveness
Authors: Alex B Diamond, S Todd Callahan, Kelly F Chain, Gary S Solomon
Journal: British Journal of Sports Medicine (2015)

Background As with most mental health disorders, the topic of hazing is not exclusive to the student athlete. However, it is also clear that the unique set of situations faced by athletes create a set of additional and difficult challenges to their mental and physical well-being. A deep-rooted culture, a lack of knowledge about hazing and its causal relationships, and a failure to act by teammates and adults all play a role in the propagation of this danger. Also, in an era where the popular press similarly celebrates and chastises episodes of hazing, it is increasingly crucial to turn to the scientific literature for guidance. Purpose To provide a comprehensive review of the scientific research on hazing in sports and to make recommendations for enhancing the approach and assistance to those in need on an individual and societal level. Study design Qualitative literature review of hazing in collegiate and school sports. Methods Databases including PubMed, Google Scholar, SPORTDiscus, EMBASE and MEDLINE were searched using standardised terms, alone and in combination, including ‘hazing’, ‘bullying’, ‘sport’, ‘athlete’, ‘college’, ‘school’ and ‘youth’. Findings Despite increased attention to its dangers, hazing remains pervasive throughout the sports world. However, many do not recognise those actions as consistent with hazing. A change in culture, increased education and awareness, along with methodologically sound strategies for action must occur in order to reduce the ill effects and cycle of hazing. To date, current information and efforts are lacking.
The risk of tuberculosis disease among HIV infected patients after 2 years of follow up
Authors: Elena Dantes, Oana Cristina Arghir, Claudia Cambrea, Milena Man, Erdin Borgazi, Sorin Rugina
Journal: European Respiratory Journal (2011)

Background:  The risk of developing Tuberculosis (TB) disease is considered to be up to 7-10% each year for persons who are infected with both Mycobacterium tuberculosis (MTB) and HIV, whereas it is of 10% over a lifetime for persons infected only with MTB. The aim of the study was to assess the risk of TB disease among HIV infected persons, based on different clues for tuberculosis9 positive diagnosis, in a TB burden area, Constanta County.   Design:  Prospective study started in 01 February 2009, ended in 31 January 2011.   Material and methods:  Evaluation for TB disease diagnosis was done in 51 HIV patients with initiated active antiretroviral therapy (HAART) after 1996 and included medical history, physical examination, Mantoux Tuberculin skin test, chest X-ray, Bactec 9050 blood culture results, bacteriological exam (Acid Fast Stains smear and Lowenstein Jensen cultures). All 51 HIV infected patients were monitored 2 years in order to diagnose the active TB diseases.   Results:  The study includes 51 HIV infected people, 22 male and 29 female, mean aged 20.5 yrs. The age of HIV infection range was between 6 months to 20 years. The risk of developing TB disease was of 21.5% (n=11/51). The prevalence of Pulmonary TB disease was greater (n=9/11;80%) than extrapulmonary forms. The symptoms of high fever, chronic cough, weight loss and dispnoea were more persistent and more severe for HIV infected patients. Tuberculin skin testing and chest X-ray evaluation were helpful for diagnosis. Only one case had positive bacteriological exam.   Conclusions:  The risk of developing active TB diseases at HIV infected people is much higher than studies reported. The bacteriologic exam is less helpful for TB diagnosis.
Prognostic factors in advanced colorectal carcinoma: A multifactorial analysis
Authors: L. Forti, S. Miraglia, E. Bertona, V. Rossi, D. Rondonotti, M. Tampellini, G. Porcile, O. Alabiso
Journal: Journal of Clinical Oncology (2005)

3732 Background: Colorectal cancer is one of the most important malignant tumours in adults and the median survival of patients with advanced disease is lower than 24 months. This study was conducted to evaluate potential prognostic factors for survival (OS) and time to progression (TTP) in patients with metastatic or locally advanced colorectal cancer (ACRC). Methods: A retrospective analysis of 453 patients with ACRC, treated from January 1994 to May 2004 with different chemotherapy schedules, was performed. Twenty-six clinical, laboratory and tumour-related parameters were investigated by multivariate logistic regression. Results: In multivariate analysis for TTP, only increased CEA levels at 6 months from first-line chemotherapy was retained an independently significant variable. In multivariate analysis for OS, a low baseline haemoglobin level (less of 12 g/dl) and increased CEA levels at 3 and 6 months from first-line chemotherapy were independent adverse prognostic factors. According to the Kaplan-Meier analysis for OS, were associated with poor survival: low performance status (ECOG more than 1), mucinous histological pattern, low baseline haemoglobin levels, elevated alkaline phosphatase levels, elevated lactic dehydrogenase levels, eosinophil count (more than 500/ul), elevated baseline CEA and Ca19–9 levels, CEA levels after 3 months and 6 months and Ca19–9 levels after 3 and 6 months from first-line chemotherapy, non-response to first-line chemotherapy and progression to first-line chemotherapy. Lung metastases alone were associated with better survival. Conclusions: These parameters could be helpful to identify different risk groups and to select more or less intensive treatments. No significant financial relationships to disclose.
Factors predictive of outcome in relapsed, refractory multiple myeloma patients treated with bortezomib, melphalan, prednisone, and thalidomide (VMPT)
Authors: A. P. Palumbo, M. T. Ambrosini, G. Benevolo, N. Pescosta, V. Callea, C. Cangialosi, T. Caravita, F. Morabito, F. Gay, M. Boccadoro
Journal: Journal of Clinical Oncology (2007)

8048 Background: In relapsed/refractory multiple myeloma (MM) patients, the addition of thalidomide and bortezomib to the standard oral melphalan/prednisone (VMPT) significantly increased response rate and progression-free survival (PFS) (Blood. 2006 Dec 5; [Epub ahead of print]). Baseline parameters which may predict outcome after VMPT have been investigated to identify which patient subgroups most benefit from this drug combination. Methods: Thirty patients with relapsed or refractory MM after 1 or 2 lines of treatment, were treated with six 35-days courses of bortezomib (3 dose levels: 1.0,1.3 and 1.6 mg/m 2 ) on days 1,4,15,22, plus melphalan (6 mg/m 2 ) and prednisone (60 mg/m 2 ) on days 1–5 and thalidomide (50 mg) on days 1–35. Several parameters such as age, β2-microglobulin, C-reactive protein, chromosome 13 abnormalities, albumin, haemoglobin, stage, creatinine, bone marrow plasmacytosis, line of therapy and dosage of bortezomib were analyzed in association with response rate and PFS, using χ2 and Cox model. Results: At least a very good partial response was achieved in 43% of patients and at least a partial response in 67%. The 1-year PFS was 61%, and the 1- year overall survival was 84%. Subgroup analyses did not show any statistical difference between responses and either age, β2 microglobulin, C-reactive protein, chromosome 13 abnormalities, line of treatment or dosage of bortezomib. Serum albumin &lt;3.5 mg/dL was loosely associated with a lower response rate (p=0.09). Factors predictive of shorter PFS were C-reactive protein = 6 mg/L (p=0.02) and 3rd line of therapy (p=0.009). Factors loosely associated with shorter PFS were β2-microglobulin = 3.5 mg/L (p=0.06) and creatinine = 2 mg/dL (p=0.09). No difference in PFS was observed between patients with or without chromosome 13 abnormalities. Conclusions: VMPT induced a high proportion of responses and appeared to overcome the poor prognosis of patients with chromosome 13q deletion. [Table: see text]
The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial
Authors: Peter Martin, Maurizio DiLiberto, Christopher E Mason, Scott A Ely, Jia Ruan, Richard R. Furman, David Chiron, Xiangao Huang, David C Madoff, Jonathan Navi, Jessica Lewis, Alison Bender, Amelyn Rodriguez, June Greenberg, Morton Coleman, Selina Chen-Kiang, John P. Leonard
Journal: Blood (2013)
Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases
Authors: S. Stremitzer, W. Zhang, D. Yang, Y. Ning, S. Stintzing, Y. Sunakawa, A. Sebio, S. Yamauchi, S. Matsusaka, A. Parekh, A. Barzi, R. El-Khoueiry, J. Stift, F. Wrba, T. Gruenberger, H.-J. Lenz
Journal: Annals of Oncology (2015)
Plasma biomarkers predictive for disease control duration in the phase I study of E7080, a multitarget kinase inhibitor
Authors: N. Yamamoto, Y. Yamada, H. Nokihara, Y. Goto, M. Tanioka, K. Yamada, F. Koizumi, N. Koyama, T. Tamura
Journal: Journal of Clinical Oncology (2009)

e14524 Background: E7080 is an oral multi-targeted kinase inhibitor of VEGFRs, PDGFRs, FGFRs and c-kit. In the phase I study for advanced solid tumors, E7080 was repeated every 3 weeks (twice daily by 2 wks-on/ 1 wk-off). The toxicities were manageable and the preliminary antitumor activity including one partial response was observed at doses up to MTD [ASCO 2008; abstract 3527]. This study was conducted to evaluate whether the change of plasma biomarkers in the E7080 phase I study could predict the antitumor activity or the disease control duration. Methods: The treatment duration was determined as a period from the first dosing to treatment failure. Plasma angiogenic proteins and circulating endothelial cells (CEC)/ progenitor cells (CEP) were measured in blood samples collected on Days 1 (pre-dose), 8 and 15 of Cycles 1 and 2. CEC and CEP population with (+) or (-) c-kit expression were analyzed by FACS. Correlation was determined by Spearman's rank correlation coefficient (r) and test for non-correlation (p). Results: 19 (76%) out of 25 evaluable patients had PR/SD including 6 (24%) patients with the treatment duration of ≥180 days. VEGF increase and sVEGFR1 and -R2 decreases in plasma were seen with the increased dose of E7080. But these changes had no correlations with disease control. E7080 decreased c-kit(+) CEC and CEP, but not c-kit(-) population. Importantly, patients showing the decrease of c-kit(+) CEC in Cycle 1 had received E7080 treatment for significantly longer duration (r=-0.468, p=0.018). The decrease of c- kit(+) CEC diminished during treatment-off for final 7 days in Cycle 1 and repeatedly decreased in Cycle 2 treatment. The decrease of c- kit(+) ratio in CEP correlated with the increase of plasma SCF (r=-0.457, p=0.021) and SDF1 (r=-0.466, p=0.018), but not with VEGF or thrombopoietin. Conclusions: The change of c-kit(+) CEC correlated with the disease control duration in the phase I study of E7080. SCF and SDF1 may play a role in c-kit(+) CEP accumulation. C-kit(+)-selective changes of CEC could be a candidate biomarker to predict the disease control duration in anti-angiogenic therapy of E7080. [Table: see text]
Perfluoroalkyl Substances, Sex Hormones, and Insulin-like Growth Factor-1 at 6–9 Years of Age: A Cross-Sectional Analysis within the C8 Health Project
Authors: Maria-Jose Lopez-Espinosa, Debapriya Mondal, Ben G. Armstrong, Brenda Eskenazi, Tony Fletcher
Journal: Environmental Health Perspectives (2016)

Background: Exposure to some perfluoroalkyl substances (PFAS), such as perfluorohexane sulfonate (PFHxS), perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), and perfluoro nonanoic acid (PFNA), may alter levels of sex hormones and insulinlike growth factor1 (IGF1) in animals.Human studies on this topic are scarce, and none have been conducted in young children.oBjectives: We investigated the relationship between levels of PFAS and estradiol, total testos terone, and IGF1 in 2,292 children (6-9 years of age) from the C8 Health Project who lived near a chemical plant in the MidOhio Valley (USA) with local contamination from PFOA.Methods: Serum samples were collected in 2005-2006 and analyzed for PFAS, sex hormones, and IGF1.Results from regression models were expressed as the adjusted percentage difference (95% CI) per sexspecific interquartile range (IQR) increment of each PFAS serum concentration.Analyses by PFAS quartiles were also conducted.results: Median concentrations of PFHxS, PFOA, PFOS, and PFNA were 8, 35, 22, and 1.7 ng/mL in boys and 7, 30, 21, and 1.7 ng/mL in girls.In boys, PFOA concentrations were significantly associated with testosterone levels (-4.9%; 95% CI: -8.7, -0.8%); PFOS with estradiol (-4.0%; 95% CI: -7.7, -0.1%), testosterone (-5.8%; 95% CI: -9.4,-2.0%), and IGF1 (-5.9%; 95% CI: -8.3, -3.3%); and PFNA with IGF1 (-3.5%; 95% CI: -6.0, -1.0%).In girls, significant associations were found between PFOS and testosterone (-6.6%; 95% CI: -10.1, -2.8%) and IGF1 (-5.6%; -8.2, -2.9%); and PFNA and IGF1 (-3.8%; 95% CI: -6.4,-1.2%).In both sexes, the magnitudes of the associations decreased monotonically across quartiles for both testosterone and IGF1 in relation to PFOS, and for IGF1 and PFNA in girls.conclusions: To our knowledge, this is the first study suggesting that PFAS are associated with lower levels of IGF1 and sex hormones in young children.